Understand the source comparison
Peptide News May 2026: Comparison of Key Trial Endpoints
The three major trials released in May 2026. TRIUMPH-2 (retatrutide), SYNCHRONIZE-NASH (survodutide), and MATTERHORN (mazdutide). Represent distinct receptor agonist strategies with different primary endpoints. This comparison clarifies which peptide mechanism
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The three major trials released in May 2026. TRIUMPH-2 (retatrutide), SYNCHRONIZE-NASH (survodutide), and MATTERHORN (mazdutide). Represent distinct receptor agonist strategies with different primary endpoints. This comparison clarifies which peptide mechanisms align with specific research or clinical goals.
- Retatrutide
- GLP-1, GIP, Glucagon
- 24.2%
- 2.02%
- Not primary endpoint
- 48
- Highest weight loss and A1C reduction; triple-agonist mechanism drives non-additive metabolic effects; GI side effects during titration are dose-limiting for ~8% of participants
- Survodutide
- GLP-1, Glucagon
- 18.6%
- 1.73%
- 47% vs 15% placebo
- 46
- Only dual-agonist with NASH resolution as primary endpoint; hepatic fat oxidation via glucagon receptor makes this the lead candidate for metabolic liver disease rather than obesity alone
- Mazdutide
- 12.1%
- 1.94%
- Not measured
- 24
- Lower weight loss than retatrutide/survodutide but superior insulin sensitivity improvement per unit of weight lost; best candidate for T2D patients with moderate obesity (BMI 30–35)
- Tirzepatide
- GLP-1, GIP
- 20.9%
- 2.58%
- 72
- Established dual-agonist with longest trial duration data; GIP receptor density in adipose tissue explains fat mass reduction exceeding GLP-1 monotherapy by ~40%
- Semaglutide 2.4mg
- GLP-1
- 14.9%
- 1.61%
- 68
- GLP-1 monotherapy benchmark; weight loss driven primarily by appetite suppression and delayed gastric emptying rather than direct adipocyte or hepatic mechanisms